EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting the α7-nicotinic acetylcholine receptor in multiple sclerosis: Implications for immunomodulation and neuroprotection

Ahmed Salem Al-Dhahi, Hayder M Al-Kuraishy, Ahmed A Mohamed, Mohamed M Salama, Yousef Saad Alanazi, Mohamed N Fawzy, Gaber El-Saber Batiha

Life Sciences · 2026-12 · 406 · 124706

DOI: 10.1016/j.lfs.2026.124706 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life Sciences, 2026-12. Verfasst von Ahmed Salem Al-Dhahi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Consultant Neurology, Department of Neuroscience, King Fahad Specialist Hospital, Saudi Arabia. Electronic address: Dhahiahmed@outlook.com. Hauptthemen laut MEDLINE: alpha7 Nicotinic Acetylcholine Receptor, Multiple Sclerosis, Immunomodulation, Neuroprotection. Die Arbeit nennt 110 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic immune-mediated disorder characterized by demyelination, axonal degeneration, and progressive neurological disability. Current disease-modifying therapies (DMTs) inadequately address neurodegeneration and remyelination failure, particularly in progressive MS. The α7-nicotinic acetylcholine receptor (α7-nAChR), a key mediator of the cholinergic anti-inflammatory pathway, has emerged as a promising therapeutic target that bridges immunomodulation and neuroprotection. This review synthesizes current evidence on the biology, distribution, and signaling of α7-nAChR in the context of MS pathogenesis. Activation of α7-nAChR suppresses NF-κB and MAPK signaling while stimulating JAK2/STAT3 pathways, reducing pro-inflammatory cytokine production and promoting regulatory immune responses. In the central nervous system (CNS), α7-nAChR activation has been reported to exert these effects in experimental models or may support oligodendrocyte resilience and remyelination. Preclinical studies in experimental autoimmune encephalomyelitis and toxin-induced demyelination models demonstrate that α7-nAChR activation alleviates inflammation, demyelination, and axonal damage. However, clinical translation faces challenges, including receptor desensitization, limited CNS penetration, and the absence of validated biomarkers. Emerging strategies, biased agonism, positive allosteric modulation, and rational combination therapies, offer promising avenues to overcome these obstacles. By integrating immunomodulatory and neuroprotective actions, α7-nAChR targeting represents a mechanistically compelling strategy for comprehensive disease modification in MS, although clinical translation remains contingent upon overcoming significant pharmacological and biomarker-related challenges. Nevertheless, its pleiotropic actions warrant further investigation in well-designed clinical trials, with potential implications for other neurodegenerative disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha7 Nicotinic Acetylcholine ReceptorMultiple SclerosisImmunomodulationNeuroprotectionNeuroprotective AgentsHumansAnimalsSignal Transduction

Stichwörter der Autor:innen

Cholinergic anti-inflammatory pathwayMultiple sclerosisNeuroinflammationNeuroprotectionα7-nicotinic acetylcholine receptor

Substanzen

alpha7 Nicotinic Acetylcholine ReceptorNeuroprotective Agents

Autor:innen und Institutionen

  • Consultant Neurology, Department of Neuroscience, King Fahad Specialist Hospital, Saudi Arabia. Electronic address: Dhahiahmed@outlook.com.
  • Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq. Electronic address: haydermutter@uomustansiriyah.edu.iq.
  • Department of Biochemistry, Faculty of Pharmacy, New Mansoura University, New Mansoura, 7723730, Egypt. Electronic address: Ahmed.abdelnaser@nmu.edu.eg.
  • Biochemistry Department, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, 11152, Egypt. Electronic address: mohamed.salama@deltauniv.edu.eg.
  • Neurology resident, Department of neuroscience, King Fahad specialist Hospital, Tabuk, Saudi Arabia. Electronic address: Yousef.Alanazi@gmail.com.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University- Arish Branch, Arish, 45511, Egypt. Electronic address: mohamed.naser@su.edu.eg.

Zitieren

APA

Al-Dhahi, A. S., Al-Kuraishy, H. M., Mohamed, A. A., Salama, M. M., Alanazi, Y. S., Fawzy, M. N., & Batiha, G. E. (2026). Targeting the α7-nicotinic acetylcholine receptor in multiple sclerosis: Implications for immunomodulation and neuroprotection. Life Sciences, 406, 124706. https://doi.org/10.1016/j.lfs.2026.124706

Vancouver

Al-Dhahi AS, Al-Kuraishy HM, Mohamed AA, Salama MM, Alanazi YS, Fawzy MN, et al. Targeting the α7-nicotinic acetylcholine receptor in multiple sclerosis: Implications for immunomodulation and neuroprotection. Life Sciences. 2026;406:124706. doi:10.1016/j.lfs.2026.124706

BibTeX
@article{AlDhahi2026,
  author = {Al-Dhahi, Ahmed Salem and Al-Kuraishy, Hayder M and Mohamed, Ahmed A and Salama, Mohamed M and Alanazi, Yousef Saad and Fawzy, Mohamed N and Batiha, Gaber El-Saber},
  title = {Targeting the α7-nicotinic acetylcholine receptor in multiple sclerosis: Implications for immunomodulation and neuroprotection},
  journal = {Life Sciences},
  year = {2026},
  volume = {406},
  pages = {124706},
  doi = {10.1016/j.lfs.2026.124706}
}
Kostenlos starten →